BRISTOL MYERS SQUIBB CO's ticker is BMY and the CUSIP is 110122108. A total of 1,311 filers reported holding BRISTOL MYERS SQUIBB CO in Q3 2014. The put-call ratio across all filers is 0.97 and the average weighting 0.4%.
About BRISTOL MYERS SQUIBB CO
Bristol Myers Squibb Co. is a leading pharmaceutical company that has been in operation for over a century. The company is known for its innovative research and development of drugs that treat a wide range of diseases, including cancer, cardiovascular disease, and HIV/AIDS.
One of the company's most significant achievements is the development of Opdivo, a drug that has revolutionized the treatment of cancer. Opdivo is a checkpoint inhibitor that helps the immune system fight cancer cells. The drug has been approved for the treatment of several types of cancer, including melanoma, lung cancer, and renal cell carcinoma.
Bristol Myers Squibb Co. has also been at the forefront of the fight against HIV/AIDS. The company's drug, Reyataz, is a protease inhibitor that is used in combination with other drugs to treat HIV/AIDS. The drug has been instrumental in helping people with HIV/AIDS live longer, healthier lives.
The company's commitment to innovation and research has made it a leader in the pharmaceutical industry. Bristol Myers Squibb Co. has a strong pipeline of drugs in development, including treatments for cancer, cardiovascular disease, and immunology.
In conclusion, Bristol Myers Squibb Co. is a pharmaceutical company that has made significant contributions to the treatment of diseases such as cancer and HIV/AIDS. The company's commitment to innovation and research has made it a leader in the industry, and its pipeline of drugs in development promises to bring new treatments to patients in need.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $276,000,000 | -76.2% | 5,075,397 | -74.4% | 0.23% | -76.8% |
| Q4 2016 | $1,158,575,000 | -4.7% | 19,824,017 | -12.1% | 0.97% | -5.1% |
| Q3 2016 | $1,216,019,000 | -24.6% | 22,553,525 | +2.8% | 1.03% | -25.2% |
| Q2 2016 | $1,613,481,000 | +21.2% | 21,937,539 | +5.2% | 1.37% | +18.7% |
| Q1 2016 | $1,331,517,000 | +6.5% | 20,843,372 | +14.7% | 1.16% | +8.3% |
| Q4 2015 | $1,250,319,000 | -49.6% | 18,176,030 | -56.6% | 1.07% | -4.3% |
| Q3 2015 | $2,479,122,000 | +124.0% | 41,876,772 | +151.8% | 1.11% | +22.4% |
| Q2 2015 | $1,106,667,000 | +32.4% | 16,632,292 | +28.4% | 0.91% | +32.3% |
| Q1 2015 | $835,692,000 | +15.7% | 12,955,889 | +5.9% | 0.69% | +11.1% |
| Q4 2014 | $722,496,000 | +62.3% | 12,238,980 | +40.7% | 0.62% | +52.1% |
| Q3 2014 | $445,246,000 | +139.0% | 8,699,657 | +126.6% | 0.41% | +138.0% |
| Q2 2014 | $186,262,000 | -50.0% | 3,839,665 | -46.4% | 0.17% | -50.6% |
| Q1 2014 | $372,367,000 | +8.5% | 7,167,790 | +11.0% | 0.35% | +7.1% |
| Q4 2013 | $343,102,000 | +10.7% | 6,455,339 | -3.6% | 0.32% | +4.9% |
| Q3 2013 | $309,865,000 | +128.5% | 6,695,440 | +120.6% | 0.31% | +116.9% |
| Q2 2013 | $135,626,000 | – | 3,034,836 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Birchview Capital, LP | 703,606 | $38,156,528 | 31.15% |
| CHIRON CAPITAL MANAGEMENT, LLC | 446,720 | $24,225,626 | 22.00% |
| Cutter Capital Management, LP | 893,800 | $48,470,774 | 9.31% |
| SECTOR GAMMA AS | 498,536 | $27,035,607 | 7.62% |
| KAHN BROTHERS GROUP INC | 831,991 | $45,118,723 | 6.69% |
| Independent Franchise Partners LLP | 14,044,326 | $761,623,798 | 6.30% |
| TERRIL BROTHERS, INC. | 245,808 | $13,330,168 | 4.59% |
| OAKTOP CAPITAL MANAGEMENT II, L.P. | 679,991 | $36,875,912 | 4.26% |
| Osher Van de Voorde Investment Management | 289,628 | $15,706,526 | 3.66% |
| BOURNE LENT ASSET MANAGEMENT INC | 162,552 | $8,815,195 | 3.56% |